{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:50:32Z","timestamp":1791820232671,"version":"4.3.4"},"reference-count":92,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"abstract":"<jats:sec id=\"ab-jrv260022-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Heart failure affects more than 6 million US adults; approximately 4% to 5% progress to advanced disease despite optimal therapy. Heart transplant is a class I guideline-recommended therapy for select individuals with advanced heart failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv260022-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>Early referral for heart transplant is guided by the \u201cI NEED HELP\u201d mnemonic, a tool that identifies patients with advanced heart failure based on criteria such as use of inotropes, persistent symptoms (New York Heart Association class III or IV), end-organ dysfunction, left ventricular ejection fraction, defibrillator shocks, hospitalizations for heart failure, persistent edema or escalating use of diuretics, and low blood pressure. Each criterion is associated with higher risk of death or first heart failure hospitalization over a median follow-up of 260 days (adjusted hazard ratio, 1.19 [95% CI, 1.11-1.27] for each additional criterion). Typical absolute contraindications to heart transplant include active systemic infection, malignancy with limited life expectancy, severe and irreversible end-organ dysfunction (eg, cirrhosis, severe pulmonary hypertension), active substance use, major untreated psychiatric illness, inadequate social support, and severe frailty. Approximately 4600 heart transplants are performed annually in the US. The mortality rate was 8.5 deaths\/100 patient-years for adults on the transplant waiting list in 2023. Leading causes of early death after transplant include primary graft dysfunction (39.5%), multiorgan failure (18.5%), and infection (13.9%). Among adults, contemporary survival rates after heart transplant are 91.5% at 1 year and 80.3% at 5 years. Lifelong maintenance immunosuppression typically combines a calcineurin inhibitor, antiproliferative agents (typically mycophenolate mofetil or azathioprine) and corticosteroids, with selective use of induction therapy (intensive immunosuppression immediately after transplant). Acute rejection requiring treatment occurs in 20% to 25% of recipients within a year, and may be treated with high-dose corticosteroids, antithymocyte globulin, and B-cell\u2013targeted therapies (such as rituximab or bortezomib). Rejection surveillance with endomyocardial biopsies of the right ventricular septum is performed 5 to 10 times within the first year after transplant. Cardiac allograft vasculopathy (chronic rejection that causes diffuse coronary narrowing) affects 29% of heart transplant recipients within 5 years and 46.8% by 10 years and is the leading cause of late mortality. Cardiac allograft vasculopathy is treated with statins, mechanistic target of rapamycin inhibitors (such as sirolimus or everolimus), and retransplant for severe cases. Infections (62.5% are bacterial, 30.0% are viral, 6.7% are fungal, and 0.8% are parasitic) and malignancy (10.7% within 5 years after heart transplant) are other leading causes of late mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv260022-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Heart transplant is the definitive therapy for carefully selected patients with advanced heart failure despite receiving optimal, guideline-directed therapy. After heart transplant, lifelong multidisciplinary care is necessary to manage immunosuppression, prevent and treat rejection and cardiac allograft vasculopathy, and monitor for infection and malignancy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2026.17622","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:30:33Z","timestamp":1791819033000},"source":"Crossref","is-referenced-by-count":0,"title":["Heart Transplant for Advanced Heart Failure"],"prefix":"10.1001","author":[{"given":"Kaushik","family":"Amancherla","sequence":"first","affiliation":[{"name":"Vanderbilt Translational and Clinical Cardiovascular Research Center, Vanderbilt University School of Medicine, Nashville, Tennessee"},{"name":"Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Shah","sequence":"additional","affiliation":[{"name":"Vanderbilt Translational and Clinical Cardiovascular Research Center, Vanderbilt University School of Medicine, Nashville, Tennessee"},{"name":"Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish S.","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly H.","family":"Schlendorf","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAnn","family":"Lindenfeld","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"jrv260022r1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.cardfail.2025.07.007","article-title":"HF STATS 2025: heart failure epidemiology and outcomes statistics: an updated 2025 report from the Heart Failure Society of America.","volume":"32","author":"Writing Committee Members","year":"2025","journal-title":"J Card Fail"},{"issue":"20","key":"jrv260022r2","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1056\/NEJMoa012175","article-title":"Long-term use of a left ventricular assist device for end-stage heart failure.","volume":"345","author":"Rose","year":"2001","journal-title":"N Engl J Med"},{"issue":"6","key":"jrv260022r3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.cardfail.2015.04.013","article-title":"Advanced (stage D) heart failure: a statement from the Heart Failure Society of America guidelines committee.","volume":"21","author":"Fang","year":"2015","journal-title":"J Card Fail"},{"issue":"7","key":"jrv260022r4","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.jchf.2017.02.020","article-title":"Progression to stage D heart failure among outpatients with stage C heart failure and reduced ejection fraction.","volume":"5","author":"Kalogeropoulos","year":"2017","journal-title":"JACC Heart Fail"},{"issue":"10","key":"jrv260022r5","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.healun.2019.08.004","article-title":"The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult heart transplantation report\u20142019; focus theme: donor and recipient size match.","volume":"38","author":"Khush","year":"2019","journal-title":"J Heart Lung Transplant"},{"issue":"5","key":"jrv260022r6","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.healun.2022.10.015","article-title":"The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients.","volume":"42","author":"Velleca","year":"2023","journal-title":"J Heart Lung Transplant"},{"issue":"2S1","key":"jrv260022r7","doi-asserted-by":"publisher","first-page":"S329","DOI":"10.1016\/j.ajt.2025.01.024","article-title":"OPTN\/SRTR 2023 annual data report: heart.","volume":"25","author":"Colvin","year":"2025","journal-title":"Am J Transplant"},{"issue":"15","key":"jrv260022r8","doi-asserted-by":"publisher","first-page":"e238","DOI":"10.1161\/CIR.0000000000001016","article-title":"Guidance for timely and appropriate referral of patients with advanced heart failure: a scientific statement from the American Heart Association.","volume":"144","author":"Morris","year":"2021","journal-title":"Circulation"},{"issue":"3","key":"jrv260022r9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.14797\/mdcvj.1512","article-title":"Who is the candidate? the heart transplant evaluation process.","volume":"21","author":"Kittleson","year":"2025","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"12","key":"jrv260022r10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.123.011003","article-title":"Detailed assessment of the \u201cI NEED HELP\u201d criteria in patients with heart failure: insights from the HELP-HF registry.","volume":"16","author":"Pagnesi","year":"2023","journal-title":"Circ Heart Fail"},{"issue":"10","key":"jrv260022r11","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.healun.2024.05.010","article-title":"International Society for Heart and Lung Transplantation guidelines for the evaluation and care of cardiac transplant candidates\u20142024.","volume":"43","author":"Peled","year":"2024","journal-title":"J Heart Lung Transplant"},{"issue":"5","key":"jrv260022r12","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.healun.2017.02.010","article-title":"\u201cI NEED HELP\u201d\u2014a mnemonic to aid timely referral in advanced heart failure.","volume":"36","author":"Baumwol","year":"2017","journal-title":"J Heart Lung Transplant"},{"issue":"21","key":"jrv260022r13","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1161\/CIRCULATIONAHA.106.615708","article-title":"Survival after heart transplantation is not diminished among recipients with uncomplicated diabetes mellitus: an analysis of the United Network of Organ Sharing database.","volume":"114","author":"Russo","year":"2006","journal-title":"Circulation"},{"issue":"7","key":"jrv260022r14","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1161\/CIR.0000000000001155","article-title":"Dual-organ transplantation: indications, evaluation, and outcomes for heart-kidney and heart-liver transplantation: a scientific statement from the American Heart Association.","volume":"148","author":"Kittleson","year":"2023","journal-title":"Circulation"},{"issue":"4","key":"jrv260022r15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.008968","article-title":"Impact of pretransplant malignancy on heart transplantation outcomes: contemporary United Network for Organ Sharing analysis amidst evolving cancer therapies.","volume":"15","author":"Batra","year":"2022","journal-title":"Circ Heart Fail"},{"issue":"2","key":"jrv260022r16","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/ajt.16207","article-title":"Frailty in heart transplantation: report from the heart workgroup of a consensus conference on frailty.","volume":"21","author":"Kobashigawa","year":"2021","journal-title":"Am J Transplant"},{"issue":"11","key":"jrv260022r17","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.3390\/jcm12113724","article-title":"Multimodal prehabilitation in heart transplant recipients improves short-term post-transplant outcomes without increasing costs.","volume":"12","author":"L\u00f3pez-Baamonde","year":"2023","journal-title":"J Clin Med"},{"key":"jrv260022r18","doi-asserted-by":"publisher","first-page":"11564","DOI":"10.3389\/ti.2023.11564","article-title":"European Society of Organ Transplantation (ESOT) Consensus statement on prehabilitation for solid organ transplantation candidates.","volume":"36","author":"Annema","year":"2023","journal-title":"Transpl Int"},{"issue":"1","key":"jrv260022r19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.healun.2024.08.001","article-title":"Trends in heart transplant outcomes for patients over the age of 70 years in the United States: an analysis of the scientific registry of transplant recipients database.","volume":"44","author":"Henricksen","year":"2025","journal-title":"J Heart Lung Transplant"},{"issue":"7","key":"jrv260022r20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.006058","article-title":"Psychosocial evaluation of candidates for heart transplant and ventricular assist devices: beyond the current consensus.","volume":"12","author":"Bui","year":"2019","journal-title":"Circ Heart Fail"},{"issue":"4","key":"jrv260022r21","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/j.1600-6143.2007.02119.x","article-title":"Smoking after cardiac transplantation.","volume":"8","author":"Botha","year":"2008","journal-title":"Am J Transplant"},{"issue":"12","key":"jrv260022r22","doi-asserted-by":"publisher","first-page":"e553","DOI":"10.1161\/CIR.0000000000000598","article-title":"Sensitization in heart transplantation: emerging knowledge: a scientific statement from the American Heart Association.","volume":"139","author":"Colvin","year":"2019","journal-title":"Circulation"},{"issue":"7","key":"jrv260022r23","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.healun.2017.02.015","article-title":"Calculated panel-reactive antibody predicts outcomes on the heart transplant waiting list.","volume":"36","author":"Kransdorf","year":"2017","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"jrv260022r24","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14907","article-title":"Efficacy of bortezomib desensitization among heart transplant candidates.","volume":"37","author":"Brinkley","year":"2023","journal-title":"Clin Transplant"},{"issue":"14","key":"jrv260022r25","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.jacc.2023.07.019","article-title":"Durable mechanical circulatory support: JACC scientific statement.","volume":"82","author":"Tedford","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"jrv260022r26","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1056\/NEJMoa1900486","article-title":"A fully magnetically levitated left ventricular assist device\u2014final report.","volume":"380","author":"Mehra","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"jrv260022r27","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1001\/jama.2022.16197","article-title":"Five-year outcomes in patients with fully magnetically levitated vs axial-flow left ventricular assist devices in the MOMENTUM 3 randomized trial.","volume":"328","author":"Mehra","year":"2022","journal-title":"JAMA"},{"issue":"4","key":"jrv260022r28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2026.102948","article-title":"Heart replacement therapy in young patients: a comparative analysis of HeartMate 3 LVAD and heart transplant using MOMENTUM 3 and UNOS registry.","volume":"14","author":"Uriel","year":"2026","journal-title":"JACC Heart Fail"},{"issue":"15","key":"jrv260022r29","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1056\/NEJMoa1800866","article-title":"Two-year outcomes with a magnetically levitated cardiac pump in heart failure.","volume":"378","author":"Mehra","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"jrv260022r30","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.004070","article-title":"Early denervation and later reinnervation of the heart following cardiac transplantation: a review.","volume":"5","author":"Awad","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"jrv260022r31","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1097\/01.TP.0000122416.70287.D9","article-title":"Atropine often results in complete atrioventricular block or sinus arrest after cardiac transplantation: an unpredictable and dose-independent phenomenon.","volume":"77","author":"Bernheim","year":"2004","journal-title":"Transplantation"},{"issue":"11","key":"jrv260022r32","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/j.healun.2005.03.019","article-title":"Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection.","volume":"24","author":"Stewart","year":"2005","journal-title":"J Heart Lung Transplant"},{"issue":"12","key":"jrv260022r33","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.healun.2013.08.011","article-title":"The 2013 International Society for Heart and Lung Transplantation working formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation.","volume":"32","author":"Berry","year":"2013","journal-title":"J Heart Lung Transplant"},{"issue":"18","key":"jrv260022r34","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1161\/CIR.0000000000000093","article-title":"Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association.","volume":"131","author":"Colvin","year":"2015","journal-title":"Circulation"},{"issue":"7","key":"jrv260022r35","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.cardfail.2025.08.021","article-title":"Antibody-independent microvascular inflammation impacts long-term risk in heart transplantation.","volume":"32","author":"Huang","year":"2026","journal-title":"J Card Fail"},{"issue":"8","key":"jrv260022r36","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.healun.2025.02.1690","article-title":"Summary of the International Society for Heart and Lung Transplantation consensus conference on emerging understanding of antibodies and antibody-mediated rejection in heart transplantation.","volume":"44","author":"Kobashigawa","year":"2025","journal-title":"J Heart Lung Transplant"},{"issue":"6","key":"jrv260022r37","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1056\/NEJMoa035717","article-title":"Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.","volume":"352","author":"Dragun","year":"2005","journal-title":"N Engl J Med"},{"issue":"7","key":"jrv260022r38","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.healun.2010.05.017","article-title":"International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy\u20142010.","volume":"29","author":"Mehra","year":"2010","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"jrv260022r39","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.122.010119","article-title":"Single-nuclear RNA sequencing of endomyocardial biopsies identifies persistence of donor-recipient chimerism with distinct signatures in severe cardiac allograft vasculopathy.","volume":"16","author":"Amancherla","year":"2023","journal-title":"Circ Heart Fail"},{"issue":"24","key":"jrv260022r40","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1161\/01.CIR.0000149745.83186.89","article-title":"Drug therapy in the heart transplant recipient: part I: cardiac rejection and immunosuppressive drugs.","volume":"110","author":"Lindenfeld","year":"2004","journal-title":"Circulation"},{"issue":"5","key":"jrv260022r41","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.15326","article-title":"Induction therapy in heart transplantation: a systematic review and network meta-analysis for developing evidence-based recommendations.","volume":"38","author":"Kugathasan","year":"2024","journal-title":"Clin Transplant"},{"issue":"10","key":"jrv260022r42","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14440","article-title":"Impact of induction therapy on outcomes after heart transplantation.","volume":"35","author":"Tzani","year":"2021","journal-title":"Clin Transplant"},{"issue":"25","key":"jrv260022r43","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1161\/01.CIR.0000150332.42276.69","article-title":"Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs.","volume":"110","author":"Lindenfeld","year":"2004","journal-title":"Circulation"},{"issue":"12","key":"jrv260022r44","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s00228-010-0902-6","article-title":"Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials.","volume":"66","author":"Penninga","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"jrv260022r45","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/00007890-199808270-00016","article-title":"A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients.","volume":"66","author":"Kobashigawa","year":"1998","journal-title":"Transplantation"},{"issue":"12","key":"jrv260022r46","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/j.healun.2024.07.002","article-title":"Long-term follow-up of the randomized, prospective Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance (SCHEDULE) trial.","volume":"43","author":"Bollano","year":"2024","journal-title":"J Heart Lung Transplant"},{"key":"jrv260022r47","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ijcard.2018.03.111","article-title":"Outcomes associated with mammalian target of rapamycin (mTOR) inhibitors in heart transplant recipients: a meta-analysis.","volume":"265","author":"Jennings","year":"2018","journal-title":"Int J Cardiol"},{"issue":"7","key":"jrv260022r48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2026.103152","article-title":"Donor-derived cell-free DNA as a prognostic biomarker after heart transplantation: the DEFINE-HT study.","volume":"14","author":"Shah","year":"2026","journal-title":"JACC Heart Fail"},{"issue":"18","key":"jrv260022r49","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1161\/CIRCULATIONAHA.121.056158","article-title":"Coronary microcirculatory dysfunction and acute cellular rejection after heart transplantation.","volume":"144","author":"Lee","year":"2021","journal-title":"Circulation"},{"issue":"10","key":"jrv260022r50","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13063","article-title":"Risk of early, intermediate, and late rejection following heart transplantation: trends over the past 25 years and relation to changes in medical management; tertiary center experience: the Sheba Heart Transplantation registry.","volume":"31","author":"Katz","year":"2017","journal-title":"Clin Transplant"},{"issue":"12","key":"jrv260022r51","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.jchf.2022.08.005","article-title":"Safety of right and left ventricular endomyocardial biopsy in heart transplantation and cardiomyopathy patients.","volume":"10","author":"Bermpeis","year":"2022","journal-title":"JACC Heart Fail"},{"issue":"9","key":"jrv260022r52","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1016\/j.transproceed.2023.08.016","article-title":"Cost and use trends of endomyocardial biopsy in heart transplant patients: a 4-year claims data analysis.","volume":"55","author":"Vilalta","year":"2023","journal-title":"Transplant Proc"},{"issue":"2","key":"jrv260022r53","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.112.001461","article-title":"Arrhythmias after heart transplantation: mechanisms and management.","volume":"1","author":"Thajudeen","year":"2012","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"jrv260022r54","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jchf.2022.11.002","article-title":"The end of endomyocardial biopsy?: a practical guide for noninvasive heart transplant rejection surveillance.","volume":"11","author":"Holzhauser","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"20","key":"jrv260022r55","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1056\/NEJMoa0912965","article-title":"Gene-expression profiling for rejection surveillance after cardiac transplantation.","volume":"362","author":"Pham","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv260022r56","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/j.1600-6143.2005.01175.x","article-title":"Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling.","volume":"6","author":"Deng","year":"2006","journal-title":"Am J Transplant"},{"issue":"12","key":"jrv260022r57","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1161\/CIRCULATIONAHA.120.049098","article-title":"Cell-free DNA to detect heart allograft acute rejection.","volume":"143","author":"Agbor-Enoh","year":"2021","journal-title":"Circulation"},{"issue":"3","key":"jrv260022r58","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14206","article-title":"Donor-derived cell-free DNA is associated with cardiac allograft vasculopathy.","volume":"35","author":"Holzhauser","year":"2021","journal-title":"Clin Transplant"},{"issue":"10","key":"jrv260022r59","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1111\/ajt.15339","article-title":"Noninvasive detection of graft injury after heart transplant using donor-derived cell-free DNA: a prospective multicenter study.","volume":"19","author":"Khush","year":"2019","journal-title":"Am J Transplant"},{"issue":"12","key":"jrv260022r60","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1053-2498(99)00098-4","article-title":"Oral steroid pulse without taper for the treatment of asymptomatic moderate cardiac allograft rejection.","volume":"18","author":"Park","year":"1999","journal-title":"J Heart Lung Transplant"},{"issue":"13","key":"jrv260022r61","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1093\/cvr\/cvab259","article-title":"Cardiac allograft vasculopathy: current review and future research directions.","volume":"117","author":"Pober","year":"2021","journal-title":"Cardiovasc Res"},{"issue":"10","key":"jrv260022r62","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.healun.2015.08.003","article-title":"The registry of the International Society for Heart and Lung Transplantation: thirty-second official adult heart transplantation report\u20142015; focus theme: early graft failure.","volume":"34","author":"Lund","year":"2015","journal-title":"J Heart Lung Transplant"},{"issue":"17","key":"jrv260022r63","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.jacc.2022.08.751","article-title":"Noninvasive physiologic assessment of cardiac allograft vasculopathy is prognostic for post-transplant events.","volume":"80","author":"Clerkin","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"jrv260022r64","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.jacc.2013.07.119","article-title":"Multiparametric cardiovascular magnetic resonance assessment of cardiac allograft vasculopathy.","volume":"63","author":"Miller","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"jrv260022r65","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.124.017197","article-title":"Comprehensive non-invasive versus invasive approach to evaluate cardiac allograft vasculopathy in heart transplantation: the CCTA-HTx study.","volume":"18","author":"Belmonte","year":"2025","journal-title":"Circ Cardiovasc Imaging"},{"issue":"9","key":"jrv260022r66","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1056\/NEJMoa022171","article-title":"Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.","volume":"349","author":"Eisen","year":"2003","journal-title":"N Engl J Med"},{"issue":"17","key":"jrv260022r67","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1161\/01.CIR.0000136812.90177.94","article-title":"Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial.","volume":"110","author":"Keogh","year":"2004","journal-title":"Circulation"},{"issue":"1","key":"jrv260022r68","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1161\/01.CIR.0000151609.60618.3C","article-title":"Drug therapy in the heart transplant recipient: part III: common medical problems.","volume":"111","author":"Lindenfeld","year":"2005","journal-title":"Circulation"},{"issue":"10","key":"jrv260022r69","doi-asserted-by":"publisher","first-page":"e284","DOI":"10.1097\/TP.0000000000003307","article-title":"Recent trends of infectious complications following heart transplantation.","volume":"104","author":"Multani","year":"2020","journal-title":"Transplantation"},{"issue":"3","key":"jrv260022r70","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"2","key":"jrv260022r71","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/00007890-199308000-00021","article-title":"Prevention of Pneumocystis carinii pneumonia in cardiac transplant recipients by trimethoprim sulfamethoxazole.","volume":"56","author":"Olsen","year":"1993","journal-title":"Transplantation"},{"issue":"18","key":"jrv260022r72","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM199204303261803","article-title":"A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation.","volume":"326","author":"Merigan","year":"1992","journal-title":"N Engl J Med"},{"issue":"11","key":"jrv260022r73","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/j.healun.2022.07.011","article-title":"Post-transplant diabetes mellitus following heart transplantation.","volume":"41","author":"Newman","year":"2022","journal-title":"J Heart Lung Transplant"},{"issue":"12","key":"jrv260022r74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2025.102710","article-title":"Cardiovascular-kidney-metabolic disease burden in children and adults following heart transplantation.","volume":"13","author":"Huang","year":"2025","journal-title":"JACC Heart Fail"},{"issue":"12","key":"jrv260022r75","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1002\/ejhf.821","article-title":"Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction.","volume":"19","author":"L\u00f6fman","year":"2017","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"jrv260022r76","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/ehf2.12585","article-title":"Incidence of end-stage renal disease after heart transplantation and effect of its treatment on survival.","volume":"7","author":"Roest","year":"2020","journal-title":"ESC Heart Fail"},{"issue":"10","key":"jrv260022r77","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJM199509073331003","article-title":"Effect of pravastatin on outcomes after cardiac transplantation.","volume":"333","author":"Kobashigawa","year":"1995","journal-title":"N Engl J Med"},{"issue":"11","key":"jrv260022r78","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/j.healun.2005.02.009","article-title":"Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients.","volume":"24","author":"Kobashigawa","year":"2005","journal-title":"J Heart Lung Transplant"},{"issue":"10","key":"jrv260022r79","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/j.jchf.2024.04.026","article-title":"Randomized trial of cholesterol lowering with evolocumab for cardiac allograft vasculopathy in heart transplant recipients.","volume":"12","author":"Broch","year":"2024","journal-title":"JACC Heart Fail"},{"issue":"1","key":"jrv260022r80","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1161\/CIRCULATIONAHA.125.077603","article-title":"Cardiac allograft vasculopathy inhibition with alirocumab: the CAVIAR trial.","volume":"153","author":"Fearon","year":"2026","journal-title":"Circulation"},{"issue":"2","key":"jrv260022r81","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jchf.2023.10.018","article-title":"Temporal trends, risk factors, and clinical outcomes of de novo lymphoproliferative disorders after heart transplantation.","volume":"12","author":"Kim","year":"2024","journal-title":"JACC Heart Fail"},{"issue":"1","key":"jrv260022r82","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jacc.2017.10.077","article-title":"Temporal trends of de novo malignancy development after heart transplantation.","volume":"71","author":"Youn","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"jrv260022r83","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1161\/01.CIR.0000151805.86933.35","article-title":"Drug therapy in the heart transplant recipient: part IV: drug-drug interactions.","volume":"111","author":"Page","year":"2005","journal-title":"Circulation"},{"issue":"9","key":"jrv260022r84","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology joint committee on clinical practice guidelines.","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"issue":"6","key":"jrv260022r85","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.cardfail.2023.09.018","article-title":"The international consortium on primary graft dysfunction: redefining clinical risk factors in the contemporary era of heart transplantation.","volume":"30","author":"Moayedi","year":"2024","journal-title":"J Card Fail"},{"issue":"9","key":"jrv260022r86","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13563","article-title":"Vaccination of solid organ transplant candidates and recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.","volume":"33","author":"Danziger-Isakov","year":"2019","journal-title":"Clin Transplant"},{"issue":"3","key":"jrv260022r87","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1056\/NEJMoa2500456","article-title":"Rapid recovery of donor hearts for transplantation after circulatory death.","volume":"393","author":"Williams","year":"2025","journal-title":"N Engl J Med"},{"issue":"10","key":"jrv260022r88","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1001\/jama.2025.25169","article-title":"Donation after circulatory death heart transplant without preimplant reanimation using rapid ultraoxygenated recovery.","volume":"335","author":"Williams","year":"2026","journal-title":"JAMA"},{"issue":"1","key":"jrv260022r89","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa2201422","article-title":"Genetically modified porcine-to-human cardiac xenotransplantation.","volume":"387","author":"Griffith","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"jrv260022r90","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41591-024-03429-1","article-title":"Transplantation of a genetically modified porcine heart into a live human.","volume":"31","author":"Griffith","year":"2025","journal-title":"Nat Med"},{"issue":"8","key":"jrv260022r91","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.healun.2024.11.017","article-title":"Single-cell RNA-sequencing identifies unique cell-specific gene expression profiles in high-grade cardiac allograft vasculopathy.","volume":"44","author":"Amancherla","year":"2025","journal-title":"J Heart Lung Transplant"},{"key":"jrv260022r92","doi-asserted-by":"publisher","DOI":"10.1038\/s44161-026-00849-9","article-title":"Dynamic cellular programs of human cardiac allograft rejection revealed by spatial transcriptomics.","author":"Amancherla","journal-title":"Nat Cardiovasc Res"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2855200\/jama_amancherla_2026_rv_260022_1791213917.22872.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:30:34Z","timestamp":1791819034000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2855200"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":92,"URL":"https:\/\/doi.org\/10.1001\/jama.2026.17622","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,12]]}}}